Teva
End to end support for patients with Huntington’s Disease and their caregivers.
Deliverables
Experience strategy, Product roadmap, Foundational design, Detailed design, Prototypes
The Challenge
For Teva, end to end care of patients with Huntington’s Disease means supporting these individuals throughout their entire journey so that there is a greater opportunity for FDA approved Austedo to make a meaningful difference. In order to increase awareness, adoption, and sustained use of Austedo, our team created a holistic portfolio of supportive solutions for patients with Huntington’s Disease and their caregivers.
The Process
The team conducted validation sessions with users in order to downselect concepts to four strategic solutions intended to launch in less than two years. Deeper explorations of each of these concepts lead to detailed value propositions for each archetype along the HD journey.
Detailed design and high fidelity prototypes were developed for both the ShareGiving app – which helps primary HD caregivers receive support from their communities – and the Communication Toolkit – which provides valuable tools, information, and digital technology to encourage healthy and meaningful conversations about the disease.
Delivery and Results
Teva can now help patients and families coping with Huntington’s Disease communicate about the condition, alleviate the often overwhelming burden of caregiving of HD patients by building a supportive ShareTeam, access valuable support groups, and utilize cutting edge VR technology to ease their emotional and behavioral symptoms.